Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Model and Strategy
AVTR logo

Avantor Navigates 2.6% Sales Dip with $300M Cost Savings Push

AVTR10-KFiling Date: 2/7/2025
Avantor, Inc.
Description

What this story covers

Avantor's 2024 10-K reveals $6.8B net sales down 2.6% amid post-COVID normalization, but operating income rose to $1.1B via divestiture gain. Cost transformation targets $300M savings by 2026; debt reduced to $3.2B, liquidity at $1.3B. Focus on biopharma innovation and efficiency positions for recovery despite competition and supply risks.

Story snapshot

CompanyAvantor, Inc.
TickerAVTR
VariantStandard detailed
Duration12:18
Filing type10-K
PeriodAnnual 2024
IndustryHealthcare & Pharmaceuticals
Accession0001722482-25-000015

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in